<?xml version="1.0" encoding="UTF-8"?>
<p id="Par3">Difluoromethylornithine (DFMO) is an irreversible inhibitor of ornithine decarboxylase (ODC), the rate-limiting enzyme involved with polyamine biosynthesis
 <sup>
  <xref ref-type="bibr" rid="CR11">11</xref>
 </sup>. Elevated ODC expression and high polyamine content have been shown in NB and other tumors, and suppression of polyamine levels by DFMO reduces tumor proliferation 
 <italic>in vitro</italic> and in xenograft models
 <sup>
  <xref ref-type="bibr" rid="CR12">12</xref>â€“
  <xref ref-type="bibr" rid="CR15">15</xref>
 </sup>. ODC inhibition by DFMO also reverses an important cancer stem cell (CSC) pathway by decreasing LIN28 and increasing Let7, and results in decreased 
 <italic>in vitro</italic> neurosphere formation in neuroblastoma cell lines
 <sup>
  <xref ref-type="bibr" rid="CR16">16</xref>
 </sup> as well as in limiting dilution assays in xenograft models
 <sup>
  <xref ref-type="bibr" rid="CR17">17</xref>
 </sup>. These findings provide the rationale to test DFMO as a maintenance therapy to prevent relapse in NB, at least in part by the potential to target NB stem cells.
</p>
